https://writinsgandwellness.com/tag/nervgens-successful-fda-meeting-sparks-phase-3-trial-hope/
NervGen's Successful FDA Meeting Sparks Phase 3 Trial Hope. Archives - Writings & Wellness
https://nervgen.com/
NervGen | NVG-291 for Spinal Cord Injury Repair
Jun 17, 2026 - NervGen is advancing NVG-291 to enable the nervous system to repair itself.
spinal cord injurynvgrepair
https://www.sahmcapital.com/news/content/nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic-tetraplegia-2026-04-07
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3...
Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia. Primary endpoint...